Nanobiotix: targets achieved for NANORAY-312

(CercleFinance.com) - Nanobiotix announces the achievement of operational milestones for NANORAY-312, an ongoing pivotal Phase III study evaluating the radioenhancer first-in-class potential of NBTXR3 in elderly patients with head and neck cancer.


This achievement entails a $20 million milestone payment from Janssen Pharmaceutica, a Johnson & Johnson subsidiary and strategic partner of the French biotech company under a worldwide licensing agreement.

Copyright (c) 2024 CercleFinance.com. All rights reserved.